Form 4: BridgeBio Pharma Director Douglas Dachille Receives Equity Grants

BridgeBio Pharma, Inc. Director Douglas A. Dachille was granted 6,589 restricted stock units and 8,425 stock options as part of his compensation, aligning his interests with shareholders.

Summary

• Douglas A. Dachille, a Director of BridgeBio Pharma, Inc. (BBIO), reported new equity grants on June 20, 2025.
• He was granted 6,589 shares of Common Stock in the form of Restricted Stock Units (RSUs) at a price of $0 per unit.
• He also received 8,425 stock options with an exercise price of $41.73 per share.
• Both the RSUs and stock options will vest in equal one-third increments annually, starting after June 20, 2025, with full vesting by June 20, 2028, contingent on his continued service on the board.
• Following these transactions, Mr. Dachille directly beneficially owns 6,589 shares of Common Stock (RSUs) and 8,425 stock options.
• Additionally, 20,000 shares of Common Stock are indirectly beneficially owned by The Dachille 2012-1 Family Trust, for which Mr. Dachille disclaims Section 16 beneficial ownership.

Sentiment

Score: 7

Explanation: The sentiment is positive as the equity grants align the director's interests with shareholders, which is generally viewed favorably. However, it does not directly reflect on the company's operational or financial performance.

Positives

• The grant of restricted stock units and stock options to a director aligns their financial interests with those of the company's shareholders, encouraging long-term value creation.
• Equity-based compensation is a standard practice for retaining and incentivizing key board members.

Future Outlook

The document indicates that the granted restricted stock units and stock options will vest over a three-year period, contingent on the director's continued service on the board of directors until June 20, 2028.

Industry Context

Equity grants to directors are a common form of compensation in the biotechnology and pharmaceutical industries, aiming to align the interests of board members with long-term shareholder value. This filing reflects a routine compensation event for a director.

Comparison to Industry Standards

• The structure of equity grants, including RSUs and stock options with multi-year vesting schedules, is a standard practice for director compensation across publicly traded companies, particularly in the life sciences sector.
• The vesting schedule of one-third per year over three years is typical for such grants, ensuring continued commitment and alignment.

Corporate Governance

Related Party Transactions

• 20,000 shares of Common Stock are indirectly owned by The Dachille 2012-1 Family Trust for the benefit of the reporting person's children, with the reporting person's spouse as trustee. The reporting person disclaims Section 16 beneficial ownership of these securities.

Stakeholder Impact

• Shareholders: The equity grants align the director's incentives with shareholder interests, potentially leading to better long-term decision-making.
• Employees: No direct impact on employees is indicated by this filing.

Next Steps

• Continued service of Douglas A. Dachille on the BridgeBio Pharma, Inc. board of directors to ensure vesting of the granted equity.
• Annual vesting of one-third of the RSUs and stock options each year after June 20, 2025, until fully vested on June 20, 2028.

Key Dates

Keywords

BridgeBio Pharma, BBIO, SEC Form 4, Insider Transaction, Restricted Stock Units, RSUs, Stock Options, Director Compensation, Equity Grant, Beneficial Ownership